Regulatory Compliance and Quality Control Risks: PolyPeptide operates in a highly regulated pharmaceutical industry, requiring strict adherence to Good Manufacturing Practice (GMP) standards. Failure to comply with regulatory requirements, quality control issues, or adverse findings from inspections by agencies like the FDA or EMA could lead to production halts, product recalls, significant fines, reputational damage, and loss of licenses, severely impacting operations and financial performance.

Client and Product Pipeline Dependency Risks: As a contract development and manufacturing organization (CDMO), a significant portion of PolyPeptide's revenue is tied to the success of its clients' drug development pipelines and commercialization efforts. The failure of a key client's drug in clinical trials, unexpected termination of a project, or consolidation among clients could lead to a substantial loss of current or future revenue. There is also a risk of high concentration on a few key clients or specific blockbuster drugs.

Competition and Pricing Pressure Risks: The CDMO market for peptides and oligonucleotides is competitive, with both specialized players and larger integrated pharmaceutical service providers. Intense competition can lead to pricing pressure on PolyPeptide's services, eroding profit margins. Competitors' advancements in technology, efficiency, or service offerings could also draw away potential clients.